Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Expected to Post Earnings of $5.32 Per Share

Analysts expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to post earnings per share of $5.32 for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Regeneron Pharmaceuticals’ earnings. The highest EPS estimate is $5.73 and the lowest is $4.55. Regeneron Pharmaceuticals reported earnings per share of $5.45 during the same quarter last year, which suggests a negative year-over-year growth rate of 2.4%. The company is scheduled to issue its next quarterly earnings report on Thursday, August 1st.

On average, analysts expect that Regeneron Pharmaceuticals will report full year earnings of $21.75 per share for the current fiscal year, with EPS estimates ranging from $18.82 to $23.25. For the next financial year, analysts forecast that the company will report earnings of $25.39 per share, with EPS estimates ranging from $22.14 to $28.75. Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $4.45 earnings per share for the quarter, missing analysts’ consensus estimates of $5.24 by ($0.79). Regeneron Pharmaceuticals had a return on equity of 26.95% and a net margin of 35.13%. The company had revenue of $1.71 billion for the quarter, compared to analyst estimates of $1.76 billion. During the same period in the previous year, the business posted $4.67 EPS. The firm’s revenue for the quarter was up 13.3% compared to the same quarter last year.

A number of research firms have weighed in on REGN. JPMorgan Chase & Co. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Friday, June 21st. BidaskClub raised shares of Regeneron Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday. Argus cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, June 18th. Leerink Swann set a $453.00 target price on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, June 11th. Finally, TheStreet cut shares of Regeneron Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Wednesday, June 5th. Three investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $395.78.

In related news, Director Joseph L. Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $305.93, for a total value of $305,930.00. Following the transaction, the director now directly owns 11,323 shares in the company, valued at approximately $3,464,045.39. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Neil Stahl sold 9,853 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $305.74, for a total transaction of $3,012,456.22. Following the completion of the transaction, the executive vice president now owns 47,450 shares in the company, valued at $14,507,363. The disclosure for this sale can be found here. Insiders own 11.84% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. Whittier Trust Co. raised its position in shares of Regeneron Pharmaceuticals by 195.7% in the 4th quarter. Whittier Trust Co. now owns 68 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 45 shares in the last quarter. Smithfield Trust Co. bought a new position in Regeneron Pharmaceuticals during the first quarter valued at about $27,000. AdvisorNet Financial Inc boosted its stake in Regeneron Pharmaceuticals by 208.0% during the fourth quarter. AdvisorNet Financial Inc now owns 77 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 52 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. bought a new position in Regeneron Pharmaceuticals during the first quarter valued at about $29,000. Finally, Captrust Financial Advisors bought a new position in Regeneron Pharmaceuticals during the fourth quarter valued at about $30,000. Hedge funds and other institutional investors own 66.91% of the company’s stock.

REGN stock opened at $312.90 on Wednesday. The company has a current ratio of 4.58, a quick ratio of 3.78 and a debt-to-equity ratio of 0.08. Regeneron Pharmaceuticals has a twelve month low of $295.27 and a twelve month high of $442.00. The business’s 50 day moving average is $309.56. The firm has a market capitalization of $34.15 billion, a PE ratio of 15.80, a P/E/G ratio of 1.47 and a beta of 1.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Recommended Story: How is a price target determined?

Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.